The two scientists won the European Inventor Award jointly in the SMEs category from the European Patent Office (EPO) for their vaccine assembly platform, the office announced on Tuesday.
The vaccine could be used to treat different types of cancer, boosting the immune system’s response to the disease and offering new hope for cancer treatment, the EPO saidExternal link.
“Derouazi and Belnoue’s invention assembles three essential components of a vaccine into a single protein [……] to produce vaccines for different types of cancer. They are intended for use alongside treatments such as surgery, chemotherapy and radiotherapy,” the EPO said.
The KISIMA platform was first used to produce a vaccine designed to treat metastatic colorectal cancer, and early-stage human trials are underway.
Derouazi studied biology and biotechnology in Geneva, Berlin and Lausanne before completing a post-doc at the French National Center for Scientific Research in Paris.
Launched in 2006, the award, which is attributed in five different categories, honours individuals and team solutions to some of the biggest challenges, the EPO said.
Popular Stories
More
Swiss Abroad
How centuries of Swiss emigrants left their mark on the US
Bodycams: essential for good law enforcement, or a privacy risk?
Did you ever come across bodycams in your place of residence and if so, how do you think the use of bodycams alter the relationship between the public and (transport) police?
This content was published on
Swiss wheelchair racer Catherine Debrunner won the 5,000 metres to bring home Switzerland’s first gold medal at the Paralympics in Paris.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.